Jemperli

News

GSK, Merck in endometrial cancer face-off

GSK and Merck & Co have both reported new clinical data with the PD-1 checkpoint inhibitors, seeking an edge in the first-line treatment of advanced endometrial cancer

News

GSK scores regular FDA approval for PD-1 inhibitor Jemperli

The checkpoint inhibitor secured confirmatory approval after an accelerated nod back in 2021.

News

Keytruda shadows GSK's Jemperli in endometrial cancer

GSK had just two months to celebrate the positive phase 3 result with its checkpoint inhibitor Jemperli as a first-line therapy for endometrial cancer, before Merck &

News

GSK trumpets Jemperli vs Keytruda data in first-line NSCLC

GSK says its PD-1 inhibitor Jemperli compared favourably with Merck & Co’s Keytruda in a head-to-head trial in previously-untreated non-small cell lung cancer (NSCLC), with numerically

News

GSK cancer division delivers good news after string of R&D s...

GSK has reported much-needed progress with two of its cancer therapies, with a phase 3 trial win for immunotherapy Jemperli in endometrial cancer and the start of a review in the EU for mye

News

GSK's Jemperli/TIM-3 immuno-oncology combo moves to ph3

GSK's latecomer to the PD-1/PD-L1 inhibitor category Jemperli has barely started to bring in revenues, and is a world away from the company's hopes of blockbuster revenues by 2031.

GSK, Merck in endometrial cancer face-off

GSK scores regular FDA approval for PD-1 inhibitor Jemperli

Keytruda shadows GSK's Jemperli in endometrial cancer

GSK trumpets Jemperli vs Keytruda data in first-line NSCLC

GSK cancer division delivers good news after string of R&D s...

GSK's Jemperli/TIM-3 immuno-oncology combo moves to ph3

Repligen builds in cell therapy with $1.5bn BioLife takeover

Discover a new era of healthcare panel engagement: Grounded ...

Jemperli

Editor's Picks